DashboardPortfoliosWatchlistCommunityDiscoverScreener
Loading...
  • Community
  • /
  • Switzerland
  • /
  • Pharmaceuticals & Biotech
  • /
  • Siegfried Holding
SFZN logo
SFZN
Siegfried Holding

Lumpy Cycles And Risks Will Limit Prospects Yet Offer Hope

AN
AnalystLowTarget
AnalystLowTarget
Not Invested
Community Contributor
Published
27 Jun 25
Updated
12 Dec 25
n/a
n/a
AnalystLowTarget's Fair Value
n/a
1Y
-29.2%
7D
1.9%
Loading
1Y
-29.2%
7D
1.9%

You can edit this narrative until Dec 13 1:10 AM. Then, changes will post as Updates.

Author's Valuation

CHF 9018.7% undervalued intrinsic discount

AnalystLowTarget Fair Value

Narrative
Updates1

Shared on 12 Dec 25

SFZN: Incoming CFO Appointment Will Support Improved Profitability Prospects

Analysts have modestly revised their price target on Siegfried Holding higher to CHF 90.00 from CHF 90.00, reflecting slightly stronger expectations for revenue growth and profitability despite a mildly higher discount rate and a marginally lower future price to earnings multiple. What's in the News Siegfried Holding appointed Tania Micki as incoming Chief Financial Officer, effective July 1, 2026, succeeding long serving CFO Reto Suter, who has held the role since 2017 (company announcement).
Read more
AnalystLowTarget Fair Value
CHF 90
18.7% undervalued intrinsic discount
Future estimation in
PastFuture02b2014201720202023202520262028Revenue CHF 1.6bEarnings CHF 211.3m
% p.a.
0
Decrease
Increase
Current revenue growth rate
7.11%
Life Sciences revenue growth rate
0.26%
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
%
0
Decrease
Increase
Current discount rate
4.87%
Calculation
CHF 211.31m
Earnings '28
x
21.62x
PE Ratio '28
=
CHF 4.57b
Market Cap '28
CHF 4.57b
Market Cap '28
/
44.45m
No. shares '28
=
CHF 102.78
Share Price '28
CHF 102.78 Share Price '28
Discounted to 2025 @ 4.88% p.a.
=
CHF 89.08
Fair Value '25
Level 5, 320 Pitt Street, Sydney
S&P Global Market Intelligence
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2025, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • About Us
  • Our People
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2025 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • Financial Services Guide